Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Phase 2

Completed

Conditions: Postoperative Ocular Pain After PRK Surgery

Interventions: Drug: SAF312
Drug: Placebo

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02961062

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Placebo
Drug: ACZ885

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT02961218

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2016-11-06

Last Posted Date: 2021-08-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1009

Registration Number: NCT02957409

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 2

Completed

Conditions: Well-differentiated Non-functional NET of Thoracic Origin
Well-differentiated Non-functional NET of Gastrointestinal Origin
Well-differentiated Non-functional NET of Pancreatic Origin
Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions: Drug: PDR001

First Posted Date: 2016-11-04

Last Posted Date: 2021-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT02955069

Locations: 🇺🇸
Rocky Mountain Cancer Centers SC-2, Denver, Colorado, United States
🇺🇸
University of TX MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 5 locations

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety

Phase 4

Completed

Conditions: Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Interventions: Biological: Ranibizumab
Radiation: Grid&Direct short pulse laser photocoagulation

First Posted Date: 2016-11-03

Last Posted Date: 2020-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT02953938

Locations: 🇯🇵
Novartis Investigative Site, Hokkaido, Japan

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Epithelial Ovarian Cancer
Renal Cell Carcinoma

Interventions: Drug: HKT288

First Posted Date: 2016-10-27

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT02947152

Locations: 🇨🇭
Novartis Investigative Site, Locarno, Switzerland

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1

Completed

Conditions: Breast Cancer
Colorectal Cancer
Lung Cancer
Renal Cancer
Hepatocellular Cancer
Pancreatic Cancer

Interventions: Drug: NIS793
Drug: PDR001

First Posted Date: 2016-10-27

Last Posted Date: 2022-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT02947165

Locations: 🇺🇸
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
🇺🇸
Huntsman Cancer Institute SC, Salt Lake City, Utah, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Letrozole
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2016-10-21

Last Posted Date: 2023-10-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3246

Registration Number: NCT02941926

Locations: 🇺🇸
Ventura County Hematology and Oncology, Oxnard, California, United States
🇺🇸
Mid Florida Hematology and Onc Ctr, Orange, Florida, United States
🇺🇸
Hope Cancer Center of East Texas, Tyler, Texas, United States

and more 69 locations

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: QCC374

First Posted Date: 2016-10-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02939599

Locations: 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer
Chordoma and Alveolar Soft Part Sarcoma
Advanced Solid Tumors

Interventions: Drug: FAZ053
Drug: PDR001

First Posted Date: 2016-10-18

Last Posted Date: 2025-01-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT02936102

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy